Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.
Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I; Collaborative Study Group. Lewis EJ, et al. Among authors: rohde rd. Am J Kidney Dis. 2011 Nov;58(5):729-36. doi: 10.1053/j.ajkd.2011.06.020. Epub 2011 Aug 26. Am J Kidney Dis. 2011. PMID: 21872376 Clinical Trial.
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M, Franke S, Wolf G, Rohde RD, Stein G; Collaborative Study Group. Busch M, et al. Among authors: rohde rd. Nephron Clin Pract. 2008;108(4):c291-7. doi: 10.1159/000127838. Epub 2008 Apr 24. Nephron Clin Pract. 2008. PMID: 18434751 Clinical Trial.
Pyridorin in type 2 diabetic nephropathy.
Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB; Collaborative Study Group. Lewis EJ, et al. Among authors: rohde rd. J Am Soc Nephrol. 2012 Jan;23(1):131-6. doi: 10.1681/ASN.2011030272. Epub 2011 Oct 27. J Am Soc Nephrol. 2012. PMID: 22034637 Free PMC article. Clinical Trial.
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE, Packham DK, Reutens AT, Wolfe R, Rohde RD, Lewis J, Atkins RC; Collaborative Study Group. Ivory SE, et al. Among authors: rohde rd. Nephrology (Carlton). 2013 Jul;18(7):516-24. doi: 10.1111/nep.12053. Nephrology (Carlton). 2013. PMID: 23506627 Clinical Trial.
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.
Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC; Collaborative Study Group. Packham DK, et al. J Am Soc Nephrol. 2012 Jan;23(1):123-30. doi: 10.1681/ASN.2011040378. Epub 2011 Oct 27. J Am Soc Nephrol. 2012. PMID: 22034636 Free PMC article. Clinical Trial.
Renal scanning 99mTc diethylene-triamine pentaacetic acid glomerular filtration rate (GFR) determination compared with iothalamate clearance GFR in diabetics. The Collaborative Study Group for The study of Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy.
Rodby RA, Ali A, Rohde RD, Lewis EJ. Rodby RA, et al. Among authors: rohde rd. Am J Kidney Dis. 1992 Dec;20(6):569-73. doi: 10.1016/s0272-6386(12)70220-2. Am J Kidney Dis. 1992. PMID: 1462984 Clinical Trial.
41 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page